| 产品详情 |
| Edit |   |
|---|
| Product Name | Troglitazone |
|---|
| Description | Troglitazone is a TZD which was approved for the treatment of insulin resistance and hyperglycemia in Type II diabetes, under the trade name Resulin™, but was withdrawn from the market due to hepatotoxicity. Troglitazone is a potent and selective PPARγ agonist. The EC50 values for transactivation of human and mouse PPARγ in a cell-based assay are 0.55 and 0.78 µM, respectively.{10670} In the same assay system, no activation of PPARα and PPAR.delta. was observed at concentrations up to 10 µM. Troglitazone binds to the PPARγ ligand-binding domain (LBD) but fails to induce interaction of the PPARγ LBD with the transcriptional coactivators SRC-1, TIF2, AIB1, p300, or TRAP220.{8555} Troglitazone also induces cell cycle arrest and apoptosis in several cancer cell lines with an EC50 of 10 µM.{10669} |
|---|
| Size | 5 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | ResulinTM |
|---|
| Gene, Accession, CAS # | CAS: 97322-87-7 |
|---|
| Catalog # | 71750-5 |
|---|
| Price | |
|---|
| Order / More Info | Troglitazone from CAYMAN CHEMICAL COMPANY |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|